Torrent Pharma forays into super specialty segment and launches Adfrar – biosimilar Adalimumab

Ahmedabad based Torrent Pharma enters New Year 2016 by announcing the launch of biosimilar Adalimumab in India under the brand name 'Adfrar'.

Adalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis. Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD). Torrent's brand 'Adfrar' will be the second biosimilar Adalimumab in the world.

Autoimmune disorders are growing ailments and Monoclonal Antibodies (MAb's) are becoming mainstay of treatment, therefore launch of 'Adfrar' is a significant step towards fortifying its presence in MAb market.

Biosimilar Rituximab - 'Toritz RA' is already launched in Rheumatology segment and now with launch of biosimilar Adalimumab - 'Adfrar', Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality.

'Adfrar' will be available as Pre Filled Syringe of 40mg. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India, for which three separate super specialty task force have been introduced. Around 100 highly trained professionals are employed in these Greenfield divisions.

About Torrent India

Torrent is amongst the top 20 companies in India with over 23% growth on MAT Nov'15 basis and currently ranked 16th.

In addition to 14 divisions in India business with over 2000 Crores turnover, three new super specialty teams have been introduced. The GI super speciality team, besides promoting biosimilar Adalimumab – 'Adfrar IB' to Gastroenterologists, will also cater to the advanced therapy needs in Hepatology. Torrent has launched new generation Hep C Antiviral Sofosbuvir - 'Sofocruz', a combination of Sofosbuvir + Ledipasvir - 'Sofocruz LP' and Daclatasvir - 'Daclacruz'. Moreover, the company has also launched Hep B Antiviral Tenofovir - 'Tenocruz'.

Torrent is already marketing biosimilar Rituximab - 'Toritz' in Oncology segment, while a super specialty division for Nephrology was also launched in 2014 with the launch of biosimilar Darbepoetin alpha - 'Darbatitor'.

The focus of Torrent Pharma India is never with business intent alone, rather it is a by product. The primary goal has always been to launch specialty niche products to address unmet medical needs arising from major life threatening diseases and reach out to maximum number of patients to offer cost effective treatment with latest quality drugs. With introduction of these new super specialty divisions, Torrent Pharma now covers most of the specialties and in near future plans to enter Urology and Ophthalmology segments to cover the therapy gaps with strategic fit products.

About Torrent:

Torrent Pharma, with annual revenues of almost Rs. 4700 Crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset).

Torrent has a full equipped Research Centre, employing almost 800 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim and Dahej have facilities to produce Formulations and Bulk drugs. The recently acquired Pithampur plant in Madhya Pradesh has capacity to produce derma products. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.